Detalhe da pesquisa
1.
Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors.
J Immunol
; 211(2): 295-305, 2023 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37256255
2.
S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced Shock.
J Infect Dis
; 217(2): 288-297, 2018 01 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29149330
3.
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
Proc Natl Acad Sci U S A
; 112(9): E966-72, 2015 Mar 03.
Artigo
Inglês
| MEDLINE | ID: mdl-25730880
4.
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.
Blood
; 125(13): 2079-86, 2015 Mar 26.
Artigo
Inglês
| MEDLINE | ID: mdl-25662332
5.
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
Blood
; 123(5): 678-86, 2014 Jan 30.
Artigo
Inglês
| MEDLINE | ID: mdl-24326534
6.
Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.
Cancer Res
; 82(7): 1396-1408, 2022 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35135810
7.
Intratumoral immunotherapy relies on B and T cell collaboration.
Sci Immunol
; 7(71): eabn5859, 2022 05 27.
Artigo
Inglês
| MEDLINE | ID: mdl-35622903
8.
Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.
Cell Chem Biol
; 29(3): 451-462.e8, 2022 03 17.
Artigo
Inglês
| MEDLINE | ID: mdl-34774126
9.
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
Blood
; 123(12): 1957-60, 2014 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24652965
10.
An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory.
bioRxiv
; 2021 May 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33880472
11.
An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory.
ACS Cent Sci
; 7(7): 1191-1204, 2021 Jul 28.
Artigo
Inglês
| MEDLINE | ID: mdl-34341771
12.
Supporting the Next Generation of Scientists to Lead Cancer Immunology Research.
Cancer Immunol Res
; 9(11): 1245-1251, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34544686
13.
Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors.
Bioorg Med Chem
; 18(17): 6404-13, 2010 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-20674367
14.
Eradication of spontaneous malignancy by local immunotherapy.
Sci Transl Med
; 10(426)2018 01 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29386357
15.
Imaging activated T cells predicts response to cancer vaccines.
J Clin Invest
; 128(6): 2569-2580, 2018 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29596062
16.
Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.
Cell Stem Cell
; 22(4): 501-513.e7, 2018 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29456158
17.
Radiotherapy and toll-like receptor agonists.
Semin Radiat Oncol
; 25(1): 34-9, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25481264
18.
Targeting CD137 enhances the efficacy of cetuximab.
J Clin Invest
; 129(6): 2595, 2019 Jun 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31157621
19.
Targeting CD137 enhances the efficacy of cetuximab.
J Clin Invest
; 124(6): 2668-82, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24837434
20.
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
J Clin Invest
; 123(6): 2447-63, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23728179